Conclusions: Activin-A is over-expressed and has anti-angiogenic effects in vitro that are not propagated in vivo, where reduced basal expression of its receptors is observed especially in severe asthma.
INTRODUCTION
Severe asthma is increasingly recognised as a distinct disease entity associated with high morbidity and healthcare costs and represents a major unmet therapeutic need [1] . In addition to airways inflammation, remodelling changes are implicated in the pathogenesis of severe asthma and can lead to irreversible airflow obstruction [2] .
Local airways angiogenesis is increasingly acknowledged to play a role in the pathophysiology of airway remodelling changes associated with asthma [3] .
Disordered angiogenesis may occur early in life and lead to accelerated lung function decline, prolonged symptoms, impaired quality of life and, even, death [3;4] . Thus, amelioration of this process represents a likely valid target for therapeutic intervention and is indeed already the subject of elaborate research [5;6] .
Angiogenesis is a multifaceted process regulated by the balance between the actions of numerous pro and anti-angiogenic factors [7] [8] [9] [10] [11] [12] , such that, no single mediator can be considered solely responsible [13] . VEGF promotes endothelial cell (EC) proliferation and differentiation and represents a key-inducer of bronchial angiogenesis in asthma through the activation of its membrane receptors, VEGFR1
and VEGFR2 [14;15] . Other pro-angiogenic factors, such as IL-17 and IL-13, have also been identified [10;16;17] . Among angiogenesis inhibitors, soluble VEGF receptor-1 (sVEGFR1), IL-18 and IL-32, exhibit potent potential effects, although, their possible roles in the context of severe asthma have not been explored [7-9;18;19] . Understanding the balance of interactions between pro and anti-angiogenic activities in the inflammatory milieu of the severe asthmatic airways remains a considerable challenge.
Activin-A is a pleiotropic cytokine, belonging to the TGF-β superfamily [20] .
While TGF-β1 signalling occurs via the TβRII, activin-A signals primarily through binding to the activin-A receptor type IIA (Act-RIIA), which results in phosphorylation of the type I receptor (termed activin-like kinase [ALK]-4) [20] .
Downstream signalling occurs via phosphorylation of receptor-regulated Smads (RSmads) that translocate to the nucleus to initiate gene transcription [20] . Both TGF-β and activin-A signalling pathways have been shown to be activated upon allergen provocation in asthma [21;22] . Emerging evidence underscores the potential impact of activin-A on the regulation of airway inflammation and remodelling [22] [23] [24] [25] [26] [27] .
Previous studies by our group and others have demonstrated an anti-inflammatory role for activin-A in various settings [28] [29] [30] [31] , while other studies have shown opposing effects [23;24] . Interestingly, although the effects of activin-A on airway vascularization have never been addressed, investigation of its angiogenic effects on other tissues has also produced conflicting results [32] [33] [34] . These discrepancies highlight the possibility that, although activin-A may be over-expressed in inflammation, its end-effects may be diverse or even ablated by modification of its signalling in particular inflammatory environments in vivo.
In the present study, we set out to investigate the expression and possible role of activin-A in regulating airways vascularity in severe asthma. We hypothesized that activin-A is produced to excess in the asthmatic bronchial mucosa by a variety of infiltrating and structural cells, including vascular endothelial cells. We further hypothesized that activin-A has the potential to regulate endothelial cell proliferation and angiogenesis but that its end effects are influenced by the integrity of its signalling pathway and the presence of other locally expressed mediators. To achieve this, we investigated the expression and origins of activin-A and its signalling molecules in the airways of patients with asthma of varying severity as well as healthy controls. We also examined both the production of activin-A and its interactions with other cytokines regulating angiogenesis in cultured human endothelial cells in vitro.
METHODS
Full methodological details are provided in the Methods section in this article's Online Supplement.
Study population
A total of 57 non-smoking subjects, including 16 non-atopic healthy controls (HC),
19 patients with persistent mild-moderate (MMA) and 22 patients with persistent severe asthma (SA), participated in the study ( when an exacerbation occurred during a two-year follow up period (n=17), prior to the administration of oral corticosteroids (OCS) (see flow-chart in supplement, Figure E1 ). Asthma exacerbations were defined as episodes of severe symptom deterioration and elevated rescue medication usage that required the administration of systemic corticosteroids or at an elevated dosage for at least three days [37] . Prior to participation in the study, all subjects provided informed written consent and the protocol was approved by the hospital's Research Ethics Committee and the Greek National Organization for Medicines. All studies were conducted according to the principles of the Declaration of Helsinki. More information regarding the study population is available in the supplement.
Fiberoptic bronchoscopy and sample collection
Bronchoscopy was performed on an outpatient basis, as previously described [38] .
After inspection of the bronchial tree, lavage was performed and BAL samples with a fluid recovery of ≥ 60% were retained for further analysis (HC n=13, MMA n= 12, SA n=19), according to the ERS Task Force guidelines regarding measurements of acellular components in BAL [39] .
Cytokine measurements
Commercially available ELISA kits were used to determine the concentration of human activin-A, IL-17A, IL-18, IL-32, VEGF and sVEGFR1 in the serum, BAL and endothelial cell culture supernatants according to the manufacturers' instructions (see supplement).
Tissue staining and measurements
Paraffin sections 3-4 μm thick were utilised for H&E and immunohistochemical staining and 6 μm thick frozen sections for immunofluorescence. Immunostaining for activin-A, ALK-4, Act-RIIA and subsequent quantification was performed as previously described [22;30;38] . Immunofluorescent staining for cellular markers was also performed as preciously described [38] . Blood vessels were identified with the vascular endothelial cell marker CD31 (goat polyclonal anti-CD31, sc-1506, 1:200, Santa Cruz, USA), and the total numbers of vessels divided by the biopsy area to determine the numbers of vessels per unit area (mm 2 ) of the sections. Extensive methodological information on tissue processing and analysis is presented in the online supplement.
Endothelial cell cultures, proliferation and in vitro angiogenesis assays
Human umbilical vein (HUVEC) and human pulmonary microvascular (HPMEC) endothelial cell lines were purchased from Merck Millipore (Darmstadt, Germany)
and PromoCell (Heidelberg, Germany), respectively. Their proliferation was measured 48h after plating (>90% confluence) using a commercially available kit (WST-8, Cayman Chemicals), as previously described [40] . For the in vitro angiogenesis assay, the V2A kit (ZHA 4000, TCS Cellworks, Buckingham, UK) was employed as previously described [40] . Recombinant human (rh)-IL-13 (10 ng/mL, R&D Systems), rh-activin-A (200 ng/mL, R&D Systems) and rh-VEGF (2 ng/mL, Biolegend) were applied for 48h at concentrations similar to previously described studies [34;41] after performing dose response and kinetic studies (see supplement,
Figure E2).
A human polyclonal anti-activin-A antibody was used for blocking activin-A (15 μg/mL, R&D). All experiments were repeated three times in tetraplicate wells. The results were expressed as percentages of medium control values.
RNA extraction and Real-Time PCR
Total RNA was isolated from HUVEC in TRI Reagent (MRC, OH, US) following the manufacturer's instructions (see supplement, Table E1 ).
Statistical analysis
Data are expressed as median and interquartile range, unless specified otherwise.
Comparisons between subject groups were performed using the Kruskal-Wallis oneway analysis of variance accompanied by Dunn's post hoc correction. The Wilcoxon matched-pair test was applied to compare activin-A expression in the stable state and during exacerbation. Correlation coefficients were calculated using the Spearman's rank method. Regarding the in vitro data, comparisons between three or more groups were analyzed by one way ANOVA followed by the Mann-Whitney U test to compare specific pairs for significant differences. A statistical software package was used for all data analysis and graph preparation (Prism v5; GraphPad, San Diego, CA, USA). A p value of ≤ 0.05 was considered significant.
RESULTS
For median values and interquartile ranges please refer to Table 1 A prominent finding of our study is that activin-A has the ability to suppress human pulmonary endothelial cell proliferation and angiogenesis in vitro, even in the presence of a robust endothelial cellular activator, such as VEGF. VEGF exerts its angiogenic effects in the asthmatic airway through its two main receptors VEGFR1
and VEGFR2 [14] , which have similar structures but divergent functions in vivo [18] .
We demonstrate here that the anti-angiogenic effects of activin-A may be propagated partly through its ability to invert the ratio of VEGFR2/VGEFR1 mRNA expression by endothelial cells, thereby modulating VEGF signalling. Furthermore, we show that activin-A stimulation has the potential to alter endothelial cell production of cytokines that affect angiogenesis, in particular by increasing the secretion of the antiangiogenic IL-18 [7;9] while reducing that of the pro-angiogenic IL-17 [10] , both at baseline and in the presence of VEGF. Finally, we also demonstrate an additional, novel biological effect of activin-A on the production of the inhibitory, circulating form of the VEGR1 by endothelial cells, through which it may indirectly further mitigate VEGF signalling [19] .
The impact of activin-A on bronchial angiogenesis has not previously been explored, although its effects on vascularisation have been investigated in other tissues with conflicting results [32] [33] [34] . Our data throw considerable light on the possible reasons for these conflicting data. The fact that angiogenesis appears to proceed in severe asthmatics in the face of elevated expression of activin-A raises the possibility that its effects may not be propagated at least partly because of modification of its signalling pathway. This hypothesis is supported by our finding that, in contrast to activin-A, the expression of its receptors, ALK-4 and Act-RIIA, was reduced, at least at the level of reduced immunoreactivity, in the bronchial tissue of severe asthmatics.
It is possible that these changes are brought about by the highly inflammatory environment of the bronchial mucosa in asthma. In support of this, we show that stimulation with IL-13 markedly reduces the expression of Act-RIIA and, to a lesser extent, ALK-4 in human pulmonary endothelial cells. IL-13 is a critical inflammatory mediator in asthma with an active signalling pathway in endothelial cells [43;44] and the ability to induce VEGF production [16;17] and mediate its effects in vivo [56] .
Inhibition of activin-A signalling by other inflammatory mediators locally in the airways, such as LPS and TNFα, has similarly been previously reported [57] . A variety of cytokines with increased expression in the bronchial mucosa of severe asthmatics, including VEGF as observed herein and by others [11] , may counteract the upregulation of angiogenic inhibitors, such as sVEGFR1 and IL-18, through which activin-A partly mediates its effects. Our observation that both sVEGFR1 and IL-18 concentrations were decreased in the BAL fluid of severe asthmatics, whereas that of VEGF was increased even in the presence of high concentrations of activin-A, are in agreement with this hypothesis (see Figure 8) . Decreased ALK-4 expression has been also reported in the airway epithelium of chronically challenged mice [58] , suggesting that allergen exposure per se could modify the expression pattern of activin-A's signalling pathway. Although we observed no differences regarding the expression of activin-A, ALK4 and Act-RIIA in the lung biopsies from atopic and non-atopic asthmatics, the possibility that allergen exposure influences their expression cannot be excluded.
The current study presents certain limitations. In an observational cross-sectional study, there is no longitudinal follow-up and it is difficult to pursue specific postulated mechanisms of disease, for which longer term studies and/or "models" may sometimes be more appropriate. Secondly, the activin-A concentrations used in 
